

ABC HOSPITAL  
 ATTN: LABORATORY  
 XYZ BUILDING  
 1234 ABCD AVENUE  
 UNKNOWN CITY, AA 12345  
 Phone: (555) 555-5555  
 Fax: (555) 555-5556



Account #  
 1234

Sample Report

<b>Patient:</b> SMITH, JOHN	
Sex:	Male SSN: 123-45-6789
Date of Birth:	02/29/1926 Age: 80 Years
Patient ID:	A0123456789
Physician:	Doe, Jane
Collection Date:	06/06/2006
Specimen:	Bone Marrow
<b>Client Specimen ID</b>	<b>Specialty Accession #</b>
01234567:ABC	006 - 1234567
<b>Received Date</b>	<b>Report Date</b>
06/07/2006	06/08/2006
Notes:	

**FINAL CHARTABLE REPORT**

**1795 – Leukemia / Lymphoma Flow EvaluatR™**



Microscopic image(s) and/or histogram(s) are a symbolic representation of key findings of this specific report and are not intended to replace a complete review and reading of the final diagnostic report provided.

**Interpretation**

**The findings provide no immunophenotypic evidence of acute leukemia or a T-cell or B-cell neoplasm.**

**Comment:** Final interpretation requires correlation with clinical and morphologic findings. Should you have any questions, please contact me.

**Morphology (Flow Cytometry Specimen)**

The cytospin and smear preparations reveal multilinear hematopoiesis with slight granulocytic left shift but no overt evidence of increased numbers of blasts. Apparent mild toxic changes are noted.

**Hematopathologist:** *[electronic signature]* **Christopher Lockhart, M.D.**



# SPECIALTY LABORATORIES

27027 Tourney Road, Valencia, CA 91355-5386  
(800) 421-7110 or (661) 799-6543  
www.specialtylabs.com

Patient: SMITH, JOHN

Specialty Accession # 006 - 1234567

## 1795 – Leukemia / Lymphoma Flow EvaluatR™

Page 2 of 2

### Tests Performed

**Markers Evaluated:** CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD34, CD45, CD56, CD64, CD117, FMC7, HLA-DR, Kappa, and Lambda

**CPT Codes:** 88184, 88185x21, 88189

### Flow Cytometry Findings

Data was produced using correlated CD45 antigen density/right angle light scatter properties, gating on cell populations (approximate percentages of all cells analyzed) listed below:

**ABNORMAL CELLS:** None Detected

**OTHER CELLS:**

- 1) <1% Non-lymphoid blasts/progenitor cells [CD34(+), CD117(+), HLA DR(+)]
- 2) 5% Polytypic, predominantly small (forward light scatter properties) B cells [CD19(+), CD20(+) with a kappa/lambda ratio = 1.5:1 and variable expression of CD23 and FMC7]
- 3) 8% Small T cells [CD3(+), CD4/CD8 ratio = 0.9:1, and non-aberrant expression of pan-T-cell antigens CD5 and CD7]
- 4) 1% NK cells [CD3(-), CD7(+), CD56 variable(+)]
- 5) 73% Granulocytic elements [CD13(+), CD16 variable(+), CD15(+)] with changes of slight left shift
- 6) 5% Monocytes [CD11b(+), CD14(+), CD64(+)]
- 7) Erythroid cells/CD45(-) cells/debris comprise the majority of the remaining events.

**DNA:** Non-contributory

**SPECIMEN VIABILITY:** 99%

**FLOW CYTOMETRY DATA ANALYST:** [electronic signature]

**Antonio Lazaro, CLS (CA)**

**REFERENCES:**

- 1) Braylan RC, Borowitz MJ, Davis BH, et.al. 1997, U.S.-Canadian Consensus Recommendations on the Immunophenotypic Analysis of Hematologic Neoplasia by Flow Cytometry. Cytometry 30; No.5; 213-63.

The hematopathologist's interpretation of these results should be considered a contributing portion of the physician's workup. Correlation with all histologic and clinical data is necessary for a final interpretation. For questions about these results, please contact Client Services (800) 421-4449.

The performance characteristics of one or more of the assays in this panel were established through validation by Specialty Laboratories, and no approval is required by the U.S. Food and Drug Administration (FDA). These tests are used for clinical purposes. They should not be regarded as investigational or for research. Specialty Laboratories is regulated under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to performed high complexity clinical testing.

**Laboratory Director:** [electronic signature]

**Michael Dugan, M.D.**

**Report Completed**